CELUW Celularity Inc.
$0.00▲ +533.33%
Healthcare
Other
Volume 154.0K
Avg Volume (10D) –
Key Metrics & Fundamentals
Market Cap
–
P/E Ratio
–
Div Yield
–%
52W Range
0.00 - 0.00
% vs 50 MA
0.00%
% vs 200 MA
–%
RSI-14
100.0
MACD Histogram
+0.0000
Beta (1Y vs SPY)
-8.26
Free Cash Flow
$1.45M
Gross Rev
$3.85M
Gross Profit
$2.39M
EBITDA
–
COGS
$1.45M
Operating Exp
$12.53M
Operating Income
-$10.13M
EBIT
-$10.13M
Pretax Income
$874,000
Net Income
$874,000
Price & Volume History
Loading chart…
Recent News
Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
GlobeNewswire · Oct 22, 2026 8:00 AM ET
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
GlobeNewswire · Sep 30, 2026 11:57 AM ET
Celularity Announces Naveen Jain to Join Board of Directors
GlobeNewswire · Sep 29, 2026 8:30 AM ET
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
GlobeNewswire · Sep 24, 2026 9:15 AM ET
Celularity Signs U.S. Manufacturing Collaboration With Potential $300 Million Purchase Opportunity
InvestorsHub · Aug 27, 2026 10:27 AM ET
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
Business Wire · Aug 27, 2026 9:00 AM ET
Celularity Provides Update Regarding Nasdaq Listing Compliance
GlobeNewswire · Aug 25, 2026 7:59 PM ET
Financial Overview - Income Statement
Quarterly
Mar 2026
See CELUW's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.